AI partnership to propel launch of National Lung Cancer Screening Programme

Digital & Innovation: Starting July 2025, the Australian Government will fund the National Lung Cancer Screening Programme (NLCSP), a crucial step in early detection of lung cancer. Aidoc, a global pioneer in clinical AI solutions, has announced the expansion of its partnership with Integral Diagnostics (IDX), a provider of AI-driven medical imaging services across Australia and New Zealand, to support the launch of the NLCSP.

This collaboration, which started four years ago, leverages Aidoc’s aiOS platform to alert radiologists and care teams to suspected and unsuspected critical findings in medical images, prioritising abnormal findings and improving the quality and timeliness of patient care across the region.

Currently, IDX is trialling a new algorithm within Aidoc’s aiOS platform that is specifically designed to notify radiologists of lung nodules and accurately measure them, enabling earlier and more appropriate intervention for lung cancer.

“Aidoc’s AI has significantly improved patient care and service. We’re keen to test and use their Chest CT AI algorithms to automate our reviews in the National Lung Cancer Screening Programme to enable us to detect disease earlier, more accurately and more efficiently,” said Dr Ian Kadish, CEO and Managing Director at Integral Diagnostics.

Aidoc’s AI technology has firmly positioned IDX as the market leader in AI-driven medical imaging in Australia and New Zealand, with its aiOS platform automatically flagging critical pathologies, including brain aneurysms, pulmonary embolisms, stroke, and brain bleeds.

Since 2019, Aidoc has processed over 600,000 cases across IDX’s entire network, including its partner facilities and hospitals. By augmenting radiologists’ workflows, it enables prioritisation of life-threatening cases when these are detected by the AI, leading to improved care and efficiency, and ultimately facilitating faster, life-saving treatments for patients.

Widely adopted across the United States and Europe, Aidoc’s aiOS platform analyses over 3 million patients monthly and is supported by more than 150 published papers and abstracts, demonstrating its proven ability to reduce costs, improve patient outcomes, and increase efficiency, solidifying its position as a leader in AI-powered radiology.

“Our partnership with Integral Diagnostics underscores our commitment to driving better health outcomes,” said Rotem Geslevich, Senior Director of Business Development at Aidoc. “As the Lung Cancer Screening initiative approaches, we are excited to play a pivotal role in saving lives.”

With AI seamlessly integrated into workflows, healthcare providers can focus on delivering the highest level of patient care. Both Aidoc and Integral Diagnostics will be featured at the RANZCR conference in Perth from 17-19 October 2024.

In reimagining healthcare, Health Industry Hub^TM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.